INTRODUCTION:The purpose of this study is to describe the effect of remdesivir on liver function test (LFT) trends when used in the treatment of COVID-19 in pregnant people.METHODS:This was a retrospective cohort study examining pregnant people with COVID-19 admitted to an academic medical center between October 1, 2020 and December 31, 2021. Patient data were obtained by querying the Data Warehouse for Health, a data repository sourced from the Epic EHR. Patient charts were reviewed to abstract missing data and to ensure accuracy of key variables. Demographics, clinical characteristics, and pregnancy outcomes were compared between those who received remdesivir and those who did not.RESULTS:The study cohort comprised 102 pregnant individuals, of whom 21 received remdesivir. Mean length of stay for patients who received remdesivir was 11.4 versus 4.2 days, and they were more likely to require intensive care unit admission (57.1% versus 2.5%) and intubation (9.5% versus 0%). Those who received remdesivir were more likely to deliver by cesarean section (62.5% versus 38.2%) and had a lower mean gestational age at delivery (35.5 weeks versus 37.8 weeks). Ten patients had a LFT doubling after treatment, and two were diagnosed with preterm preeclampsia. Patients with LFT doubling were more likely to be delivered by cesarean section (87.5% versus 16.8%) and had a lower mean gestational age at delivery (33.2 weeks versus 38.2 weeks).CONCLUSION:Thirty-three percent of patients treated with remdesivir had a doubling in LFTs. Two had increases attributed to preterm preeclampsia. Further research is essential to elucidate the autonomous effects of remdesivir, COVID-19, and preeclampsia, on liver function.
Importance Posterior compartment surgery is considered a risk factor for postoperative urinary retention because of the impact of postoperative pain on the pelvic floor; however, few studies have examined the association between posterior compartment reconstructive surgery and urinary retention.Objective The aim of the study was to compare rates of urinary retention in patients undergoing vaginal reconstructive surgery, without hysterectomy, in the posterior compartment only versus any apical and/or anterior compartment (with or without posterior compartment). Study Design In this retrospective cohort study, we evaluated patients who underwent surgery, without hysterectomy, in the posterior compartment only versus any apical and/or anterior compartment (with or without posterior compartment) from January 2015 to November 2020. Our primary outcome was rate of postoperative urinary retention, defined as a failed voiding trial before discharge. Secondary outcome was days of catheterization. Multivariable logistic regression was performed to assess variables associated with a failed voiding trial. Results Of 362 patients, 141 (39.0%) underwent surgery in the posterior compartment only and 221 (61.0%) underwent vaginal apical and/or anterior compartment surgical procedures. Rate of retention was significantly lower in the posterior compartment only group (9.9% vs 41.6%, P < 0.001). The median numbers of days of catheterization were significantly fewer in the posterior compartment only group (0 [0,0] vs 0 [0,3], P < 0.001). In multivariable logistic regression, posterior compartment only surgery was associated with passing the voiding trial (odds ratio, 6.0; 95% confidence interval, 2.97-12.03). Conclusions Rates of postoperative urinary retention after surgery in the posterior compartment are low, and these patients may not require formal voiding trials after surgery.
young women with cancer than in controls of the same age group. This suggests a systemic effect of cancer both at the ovary and blood levels in young women. In older women, differences in TL between controls and patients were harder to find. Possibly a higher number of older patients would clarify the results.IMPACT STATEMENT: The evidence of the distal effect of cancer in the ovary, indicates the urgent need of ovarian fertility preservation before ovarian function decreases. This may facilitate pregnancy after cancer therapy.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.
customersupport@researchsolutions.com
10624 S. Eastern Ave., Ste. A-614
Henderson, NV 89052, USA
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Copyright © 2024 scite LLC. All rights reserved.
Made with 💙 for researchers
Part of the Research Solutions Family.